Singapore, Sep 09, 2010: Lotus Pharmaceuticals, a pharma company in China, said it has engaged RedChip to lead its public and investor relations efforts.

"RedChip's integrity, professionalism, and established reputation for improving investor visibility in the small-cap space prompted us to choose them to lead our ongoing investor relations efforts," stated Dr Zhongyi Liu, Chairman, CEO, Lotus Pharma. "Their platform of media and investor relations services is the most comprehensive in the business. We look forward to working with them, and we are confident that RedChip's programs will enable us to build strong, long-term relationships with investors."

"We are pleased to have the opportunity to represent Lotus," said Mr Dave Gentry, President and CEO of RedChip. "China is one of the world's largest and fastest-growing pharmaceutical markets, with annual sales expected to reach $24 billion in 2010. Continued economic development within China, as well as Chinese government policies aimed at expanding citizens' access to healthcare, is anticipated to drive future growth in this sector. With its strong R&D capabilities, innovative product development pipeline and well-established national distribution network, Lotus is poised to become a market leader. We look forward to introducing them to our investor network as we implement a comprehensive investor relations program that includes research, radio programming, road shows and investor conferences."